Infigratinib 0.016 mg/kg
QBGJ398-201
Phase 2 small_molecule completed
Quick answer
Infigratinib 0.016 mg/kg for Achondroplasia is a Phase 2 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BridgeBio Oncology Therapeutics
- Indication
- Achondroplasia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed